Adaptive Biotechnologies Plans to Split Its MRD and Immune Medicine Units
The company expects to decide the best path by year-end 2026.
/ 1650 items
#XY↓
H.C. Wainwright Says CNTX Stock Drop Is 'Overdone' After CTIM-76 Ovarian Cancer Data
Context Therapeutics reported positive Phase 1 data for CTIM-76 in heavily pretreated platinum-resistant ovarian cancer, showing a 29% response rate and good safety, but the stock fell due to small trial size.
CMS Plans Permanent Medicare Drug Price Negotiations Starting 2029 – What It Means for Big Pharma
Medicare plans drug price cuts from 2029, hitting pharma stocks, but long-term impact may be limited by legal and market protections.
enGene Lays Off 50% of Staff and Stops Patient Enrollment to Save Cash
enGene is reducing its workforce by ~50% and has stopped patient enrollment in three additional LEGEND trial cohorts to preserve cash while focusing on its pivotal data and planned BLA filing.
Analysts Reiterate Buy Ratings on Intellia as lonvo-z Shows Deeper Benefits in HAELO Trial
Intellia’s one-time gene therapy cut HAE attacks ~90%, boosting hopes for a lasting treatment; FDA review underway, launch possible in 2027.
Oppenheimer Sees 440% Upside in Acrivon Therapeutics as Key ACR-368 Data Approaches
Cancer drug ACR-368 shows strong early results in endometrial trials biomarker-driven response.